Modern Slavery Statement

For the financial year ended 31 December 2017

Chief Executive Officer’s Statement:

Morningside Pharmaceuticals Ltd (MPL) is committed to preventing acts of modern slavery and human trafficking from occurring within its business and supply chains, including subcontractors and partners. As part of the pharmaceutical industry, MPL recognises that it has a responsibility to take a robust approach to slavery and human trafficking in order to tackle hidden labour exploitation proactively. 

Morningside Pharmaceuticals Ltd:

Morningside Pharmaceuticals Ltd is a manufacturer, wholesaler and exporter of branded and generic medicines and healthcare products worldwide. It is our vision to make quality healthcare an affordable and accessible reality throughout the world.  The Company acknowledges its responsibility to the Modern Slavery Act 2015 and will ensure transparency within the organisation and with the supply of goods and services to the organisation. 

Our Supply Chains:

The Company purchases and manufactures licensed medicines and Healthcare products from the European Union (EU) and other non EU countries. We believe that the area with the greatest risk of these practices is within our Contract Manufacturing Organisations (CMOs) outside the EU. 

Effective January 2018, we will request that our ‘Greatest Risk’ CMOs complete our Anti-Modern Slavery and Bribery Ethical Self- Assessment Questionnaire annually as part of the due diligence process. They will be asked to provide information with regards to their policies on human rights and workplace conditions to allow MPL to ensure these are consistent with the requirements of the Modern Slavery Act 2015.

Morningside Pharmaceuticals Limited’s Responsibilities:

The CEO, Directors and Management shall take responsibility for implementing this policy statement and its objectives, and shall provide adequate resources (training, etc.) and investment to ensure that Modern Slavery and Human Trafficking is not taking place within the organisation and its supply chains. 

Education and Training:

The Quality Assurance Unit in conjunction with the Human Resources Manager will take responsibility for ensuring that all MPL employees are aware of the Company’s statement of compliance with the Modern Slavery Act 2015 and its on-going commitments, and must also ensure that this statement is displayed on the company website and included in the Employee Handbook.

Training will be provided to employees and Management at MPL who have direct responsibility for supply chain management, particularly with respect to the mitigation of risks within the supply chain. 

Morningside firmly believes that Modern Slavery and Human Trafficking are serious crimes that violate the fundamental human rights to which we are all entitled. Morningside is pleased to present this statement pursuant to section 54(1) of the Modern Slavery Act 2015 with the aim of outlining the Company’s stance on Modern Slavery and Human Trafficking, and hope that the measures being put into place will further develop a robust system for identifying Modern Slavery and Human Trafficking going forward.

Signed by Dr Nik Kotecha OBE, Chief Executive, of Morningside Pharmaceuticals Ltd.  

Last edited on January 5, 2018

Click here to download Morningside Pharmaceuticals Anti Modern Slavery and Human Trafficking Statement.